CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer
Recruiting · NCT05795335 · Observational (researchers observe without assigning treatment)
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This is an ambispective, single-center study to evaluate the survival outcomes, adverse events and predictive biomarkers for CDK4/6 inhibitors in patients with hormone receptor-positive advanced breast cancer.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Aged ≥18 and older
- Confirmed diagnosis of hormone receptor-positive breast cancer.
- Subjects with locoregionally recurrent or metastatic disease not amenable to curative therapy.
- Subjects have received or plan to receive CDK4/6 inhibitors for advanced disease.
- ECOG 0-2
- Adequate organ function
Exclusion criteria
- Subjects disable to swallow pills.
- History of immunodeficiency disease
Where it is running
1 location listed.
- Renji Hospital, School of Medicine, Shanghai Jiao Tong University - Shanghai, Shanghai Municipality, China